chloropropanoylpretadalafil
Chloropropanoylpretadalafil was identified in a supplement by FDA forensic chemists. Its chemical structure is established. Whether it inhibits PDE5, improves erections or is safe in humans remains unknown.
Small-molecule tadalafil-related analog
- The original paper isolated the compound from a sexual-enhancement supplement.
- It is distinct from chloropretadalafil, nortadalafil, and tadalafil.
- Chemical characterization is not clinical validation.
What did the researchers identify?
The researchers found a tadalafil-related compound with a chloropropanoyl modification and named it chloropropanoylpretadalafil. It differs from chloropretadalafil.
Kern et al., primary structural characterization
Analytical identity or detection study
Kern SE, Lorenz LM, Lanzarotta A, Nickum EA, Litzau JJ. Isolation and structural characterization of a new tadalafil analog (chloropropanoylpretadalafil) found in a dietary supplement. Journal of pharmaceutical and biomedical analysis. 2016. DOI 10.1016/j.jpba.2016.05.038.
FDA forensic chemists isolated a supplement constituent and characterized its chloropropanoyl modification using HPLC-UV, GC/FTIR/MS and accurate mass. The reported ion is m/z 441.1216. This is a single-product chemical investigation, not an administered-human or animal efficacy experiment. No functional PDE5 IC50, clinical PK or biological safety outcome appears in the primary abstract.
- Participants / model
- A sexual-enhancement supplement sample
- Follow-up
- Analytical investigation
- Study design
- Primary chemical isolation and structural characterization
PubChem: chloropropanoylpretadalafil chemical identity
Government chemical identity database
National Library of Medicine. PubChem CID 140466495.
C23H21ClN2O5; molecular weight 440.9 g/mol.
- Participants / model
- Chemical record
- Follow-up
- Living database
- Study design
- Curated structure record
Formula and molecular weight establish the recorded structure, not the contents of a retail product or an effective dose.
Read the original sourceWhat did the original investigation establish?
The investigators isolated a supplement constituent and characterized its chloropropanoyl modification using chromatography, spectroscopy and accurate mass. They did not test it as a treatment.
The correct primary record is PMID 27337189. Its reported protonated ion is m/z 441.1216; an ion formula should not be treated as the neutral molecule’s formula. The abstract supplies no functional PDE5 IC50, clinical PK or biological safety outcome.
Kern et al., primary structural characterization
Analytical identity or detection study
Kern SE, Lorenz LM, Lanzarotta A, Nickum EA, Litzau JJ. Isolation and structural characterization of a new tadalafil analog (chloropropanoylpretadalafil) found in a dietary supplement. Journal of pharmaceutical and biomedical analysis. 2016. DOI 10.1016/j.jpba.2016.05.038.
FDA forensic chemists isolated a supplement constituent and characterized its chloropropanoyl modification using HPLC-UV, GC/FTIR/MS and accurate mass. The reported ion is m/z 441.1216. This is a single-product chemical investigation, not an administered-human or animal efficacy experiment. No functional PDE5 IC50, clinical PK or biological safety outcome appears in the primary abstract.
- Participants / model
- A sexual-enhancement supplement sample
- Follow-up
- Analytical investigation
- Study design
- Primary chemical isolation and structural characterization
What is known about human risk?
The study provides no clinical adverse-event profile, interaction data, human half-life or therapeutic dose. It also cannot tell whether the compound improves erectile function.
Kern et al., primary structural characterization
Analytical identity or detection study
Kern SE, Lorenz LM, Lanzarotta A, Nickum EA, Litzau JJ. Isolation and structural characterization of a new tadalafil analog (chloropropanoylpretadalafil) found in a dietary supplement. Journal of pharmaceutical and biomedical analysis. 2016. DOI 10.1016/j.jpba.2016.05.038.
FDA forensic chemists isolated a supplement constituent and characterized its chloropropanoyl modification using HPLC-UV, GC/FTIR/MS and accurate mass. The reported ion is m/z 441.1216. This is a single-product chemical investigation, not an administered-human or animal efficacy experiment. No functional PDE5 IC50, clinical PK or biological safety outcome appears in the primary abstract.
- Participants / model
- A sexual-enhancement supplement sample
- Follow-up
- Analytical investigation
- Study design
- Primary chemical isolation and structural characterization
Why do some source links describe a different compound?
The cited PMC manuscript body describes chloropropanoylpretadalafil, but its header points to a different 2-hydroxyethylnortadalafil record. That is a bibliographic mismatch, not replication.
The manuscript describes a ten-capsule composite and coexisting analogs, with insufficient purity or quantity for definitive NMR work. Its header points to a different 2-hydroxyethylnortadalafil record, so it is not independent replication. The quantitative chloropropanoylpretadalafil result comes from PMID 27337189.
Kern et al., primary structural characterization
Analytical identity or detection study
Kern SE, Lorenz LM, Lanzarotta A, Nickum EA, Litzau JJ. Isolation and structural characterization of a new tadalafil analog (chloropropanoylpretadalafil) found in a dietary supplement. Journal of pharmaceutical and biomedical analysis. 2016. DOI 10.1016/j.jpba.2016.05.038.
FDA forensic chemists isolated a supplement constituent and characterized its chloropropanoyl modification using HPLC-UV, GC/FTIR/MS and accurate mass. The reported ion is m/z 441.1216. This is a single-product chemical investigation, not an administered-human or animal efficacy experiment. No functional PDE5 IC50, clinical PK or biological safety outcome appears in the primary abstract.
- Participants / model
- A sexual-enhancement supplement sample
- Follow-up
- Analytical investigation
- Study design
- Primary chemical isolation and structural characterization
Author manuscript with bibliographic mismatch
Author manuscript
Kern SE, Nickum EA, Flurer RA, Toomey VM, Litzau JJ. Isolation and structural characterization of a new tadalafil analog (2-hydroxyethylnortadalafil) found in a dietary supplement. Journal of pharmaceutical and biomedical analysis. 2015. DOI 10.1016/j.jpba.2014.10.021.
The manuscript body describes chloropropanoylpretadalafil in a composite of ten capsules, with coexisting nortadalafil and N-ethyltadalafil and too little purity or material for definitive NMR elucidation. It points to a 2002 patent intermediate. Its header, PMID 25462127 and DOI 10.1016/j.jpba.2014.10.021, identifies a different 2-hydroxyethylnortadalafil paper. This mismatched record is not independent replication; the quantitative chloropropanoylpretadalafil result comes from PMID 27337189.
The manuscript introduction and methods do not match its bibliographic header.
Read the original sourceStudies and sources
Kern et al., primary structural characterization
Analytical identity or detection study
Kern SE, Lorenz LM, Lanzarotta A, Nickum EA, Litzau JJ. Isolation and structural characterization of a new tadalafil analog (chloropropanoylpretadalafil) found in a dietary supplement. Journal of pharmaceutical and biomedical analysis. 2016. DOI 10.1016/j.jpba.2016.05.038.
FDA forensic chemists isolated a supplement constituent and characterized its chloropropanoyl modification using HPLC-UV, GC/FTIR/MS and accurate mass. The reported ion is m/z 441.1216. This is a single-product chemical investigation, not an administered-human or animal efficacy experiment. No functional PDE5 IC50, clinical PK or biological safety outcome appears in the primary abstract.
- Participants / model
- A sexual-enhancement supplement sample
- Follow-up
- Analytical investigation
- Study design
- Primary chemical isolation and structural characterization
PubChem: chloropropanoylpretadalafil chemical identity
Government chemical identity database
National Library of Medicine. PubChem CID 140466495.
C23H21ClN2O5; molecular weight 440.9 g/mol.
- Participants / model
- Chemical record
- Follow-up
- Living database
- Study design
- Curated structure record
Formula and molecular weight establish the recorded structure, not the contents of a retail product or an effective dose.
Read the original sourceAuthor manuscript with bibliographic mismatch
Author manuscript
Kern SE, Nickum EA, Flurer RA, Toomey VM, Litzau JJ. Isolation and structural characterization of a new tadalafil analog (2-hydroxyethylnortadalafil) found in a dietary supplement. Journal of pharmaceutical and biomedical analysis. 2015. DOI 10.1016/j.jpba.2014.10.021.
The manuscript body describes chloropropanoylpretadalafil in a composite of ten capsules, with coexisting nortadalafil and N-ethyltadalafil and too little purity or material for definitive NMR elucidation. It points to a 2002 patent intermediate. Its header, PMID 25462127 and DOI 10.1016/j.jpba.2014.10.021, identifies a different 2-hydroxyethylnortadalafil paper. This mismatched record is not independent replication; the quantitative chloropropanoylpretadalafil result comes from PMID 27337189.
The manuscript introduction and methods do not match its bibliographic header.
Read the original sourceWhy is chloropropanoylpretadalafil in D tier?
D: a characterized supplement ingredient with unmeasured clinical effects and safety. The grade describes missing biological evidence; it does not establish safety or superiority to the other analogs.